Abstract：
Generalized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pregnant women has not been reported to date. Here, we report a pregnant woman with refractory GPP who did not respond well to systemic steroids. Administration of spesolimab resulted in complete control of the disease and the birth of a healthy baby. Our case demonstrates that IL-36RN inhibitors are a potentially effective and safe treatment option for GPP in pregnancy.
摘要：
妊娠中的全身性脓疱型银屑病（3GPP）可导致母亲和胎儿的严重并发症。这种疾病的治疗具有挑战性，尤其是在顽固和严重的情况下。直到现在,没有基于证据的指导原则来治疗妊娠期的3GPP.Spesolimab,一种抗IL-36受体的人单克隆抗体，最近引起了人们的注意，作为一种新的疗法，对GPP耀斑。这种生物制剂可以快速和持续地控制3GPP耀斑的症状，尽管迄今为止尚未报道其在孕妇中的使用。这里,我们报告了1名患有难治性GMP的孕妇,其对全身性类固醇的反应不佳.spesolimab的施用导致疾病的完全控制和健康婴儿的出生。我们的案例表明，IL-36RN抑制剂是妊娠期GPP的潜在有效和安全的治疗选择。
